Retatrutide
Retatrutide is Lilly's investigational once-weekly GLP-1/GIP/glucagon triple agonist. Jastreboff 2023 reported up to 24.2% body-weight loss at 48 weeks, but FDA says retatrutide is not approved and cannot legally be compounded.
Retatrutide scored 4.5 / 10 (⚠️ Proceed with caution) on the BioHarmony scale as a Substance → Pharmaceutical / Drug → Other Pharmaceutical.
What It Is
Retatrutide is an investigational once-weekly peptide drug from Eli Lilly that activates three metabolic hormone receptors at once: GLP-1R, GIPR, and glucagon receptor. In practice, that means appetite suppression, improved insulin signaling, and a glucagon-driven push toward hepatic fat oxidation and thermogenesis in the same molecule. This is why retatrutide sits beyond semaglutide and tirzepatide in pharmacological ambition.
The efficacy signal is not subtle. Jastreboff 2023 reported up to 24.2% body-weight loss at 48 weeks in adults with obesity or overweight without diabetes. Rosenstock 2023 reported HbA1c reductions up to -2.02% and body-weight loss up to -16.94% in type 2 diabetes. Sanyal 2024 added a strong liver-fat signal in MASLD, though the audit flagged that substudy as smaller than the Track 1 surveillance threshold.
That upside is why retatrutide is interesting. The regulatory and safety context is why retatrutide does not score like a proven therapy yet. FDA says retatrutide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot legally be used in compounding. Real-world access outside trials is therefore research-peptide supply, not pharmacy-grade medicine. Until Phase 3 publications, cardiovascular outcomes, longer safety exposure, and an approved label exist, the correct frame is high-potential investigational drug, not casual weight-loss biohack.
Terminology
For regulatory context, see FDA's page on unapproved GLP-1 drugs.
- GLP-1: Glucagon-like peptide-1, an incretin hormone that raises glucose-dependent insulin secretion, slows gastric emptying, and suppresses appetite.
- GIP: Glucose-dependent insulinotropic polypeptide, an incretin hormone that helps amplify insulin signaling and may affect adipose tissue energy handling.
- Glucagon: A hormone that increases hepatic glucose output and, in this drug design, is used to promote fat oxidation and energy expenditure.
- Triple agonist: A single molecule that activates three receptor systems. Retatrutide targets GLP-1R, GIPR, and glucagon receptor.
- GLP-1RA: GLP-1 receptor agonist. Semaglutide and liraglutide are examples.
- HbA1c: Glycated hemoglobin, a roughly 3-month marker of average blood glucose.
- MASLD: Metabolic dysfunction-associated steatotic liver disease, the updated term for fatty liver disease linked to metabolic dysfunction.
- MASH: Metabolic dysfunction-associated steatohepatitis, inflammatory fatty liver disease that can progress to fibrosis.
- MACE: Major adverse cardiovascular events, commonly cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
- MTC: Medullary thyroid carcinoma, a thyroid cancer relevant to incretin-class labeling discussions.
- MEN2: Multiple endocrine neoplasia type 2, a genetic syndrome associated with MTC risk.
- Dysesthesia: Abnormal sensation such as tingling, burning, or altered skin sensation.
- TRIUMPH: Lilly's Phase 3 retatrutide program for obesity and weight-related complications.
- TRANSCEND-T2D: Lilly's Phase 3 retatrutide program in type 2 diabetes.
- Gray-market: Product sold outside regulated pharmacy channels, usually labeled research-use-only and not approved for human therapeutic use.
- Compounded: A pharmacy-prepared drug. FDA says retatrutide cannot legally be used in compounding because it is not an approved drug component.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 1 route and 5 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous injection | Investigational once-weekly injection; Lilly-manufactured product inside clinical trials | 2 mg to 12 mg weekly with stepwise escalation every 4 weeks in Phase 2 and Phase 3 protocols No approved dose exists. Trial material is manufactured and monitored under Lilly protocols. | 0.5 mg to 12 mg weekly is reported in gray-market use; some users skip titration or exceed trial ranges Research-peptide sourcing sits outside pharmacy channels. Dose accuracy, sterility, identity, and storage are not guaranteed. |
Protocols
Obesity trial titration Clinical
- Dose
- 2 mg, then 4 mg, then 8 mg or 12 mg weekly depending on protocol and tolerability
- Frequency
- Weekly
- Duration
- Continuous; 48 weeks published in Phase 2 obesity, 68 weeks reported in TRIUMPH-4 topline
[Jastreboff 2023](https://pubmed.ncbi.nlm.nih.gov/37366315/) reported up to 24.2% body-weight loss at 48 weeks at the 12 mg dose.
Type 2 diabetes trial titration Clinical
- Dose
- Retatrutide target doses from 0.5 mg to 12 mg weekly, with escalation arms starting at 2 mg or 4 mg
- Frequency
- Weekly
- Duration
- 36 weeks published in Phase 2; 40 weeks reported in 2026 Phase 3 topline
[Rosenstock 2023](https://pubmed.ncbi.nlm.nih.gov/37385280/) reported HbA1c change up to -2.02% at 24 weeks and body-weight change up to -16.94% at 36 weeks.
MASLD / MASH investigational protocol Clinical
- Dose
- 12 mg weekly after titration in the published phase 2a substudy
- Frequency
- Weekly
- Duration
- 24 weeks for liver-fat endpoints in the published substudy
The audit verified [Sanyal 2024](https://www.nature.com/articles/s41591-024-03018-2) as a phase 2a MASLD source but flagged the sample as below the Track 1 n>=100 threshold.
Knee osteoarthritis with obesity trial protocol Clinical
- Dose
- 2 mg start, stepwise titration every 4 weeks to 9 mg or 12 mg weekly
- Frequency
- Weekly
- Duration
- 68 weeks in TRIUMPH-4 topline
Lilly's [TRIUMPH-4 press release](https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average) reported weight and WOMAC pain improvements, but full peer-reviewed data were not yet published.
Gray-market self-experimentation Anecdotal
- Dose
- Variable; often 0.5 mg to 12 mg weekly
- Frequency
- Weekly or irregular
- Duration
- Unknown
Not recommended. No approved product, no compounding path, no standardized quality control, and no clinician-validated microdose protocol.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 3.67
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 4.9 | 1.225 | |
| Breadth of Benefits | 15% | 3.8 | 0.570 | |
| Evidence Quality | 25% | 2.5 | 0.625 | |
| Speed of Onset | 10% | 3.8 | 0.380 | |
| Durability | 10% | 1.5 | 0.150 | |
| Bioindividuality Upside | 15% | 4.8 | 0.720 | |
| Total | 3.670 |
Upside Rationale
Retatrutide's upside is large weight, glucose, waist, and liver-fat signals from triple incretin pharmacology, but the useful read is narrower than the marketing version. Jastreboff 2023 supports the main direction of benefit, and Rosenstock 2023 helps explain where that signal may matter in real use. Mechanistically, GLP-1, GIP, and glucagon receptor agonism changes appetite, glucose handling, and energy expenditure, which makes the intervention plausible across several BioHarmony use cases. The strength is strongest when the goal matches body composition, glucose, liver fat, blood pressure, GI symptoms, gallbladder risk, and lean mass. Retatrutide is weaker when the goal is vague optimization, because long-term safety, muscle preservation, discontinuation effects, and real-world sourcing remain unsettled. That makes Retatrutide a reasonable tool when the experiment is specific, measured, and time-bounded.
Efficacy (4.9/5.0): Retatrutide's strongest citable result is up to 24.2% body-weight loss at 48 weeks in Jastreboff 2023. The curve had not clearly plateaued, which is rare in obesity pharmacotherapy. Type 2 diabetes data are also strong: Rosenstock 2023 reported HbA1c reductions up to -2.02% and body-weight loss up to -16.94%. Xie 2024 ranked retatrutide 12 mg and 8 mg as the strongest weight-loss options in a 27-RCT network meta-analysis. This is historic magnitude for an outpatient metabolic drug, but it remains an efficacy score for a trial compound, not an approved product.
Breadth of Benefits (3.8/5.0): Retatrutide already touches several high-value disease clusters: obesity, glycemia, waist circumference, blood pressure, triglycerides, liver fat, knee osteoarthritis in topline Phase 3, and obstructive sleep apnea in ongoing Phase 3. Pallavi 2025 adds a kidney-comorbidity review signal, and Giblin 2026 documents the breadth of the TRIUMPH registrational program. Still, breadth is not the same as completed outcomes. Cardiovascular events, kidney outcomes, sleep apnea endpoints, and MASH histology need completed and peer-reviewed data before retatrutide earns the kind of breadth score semaglutide has after SELECT-like outcomes evidence.
Evidence Quality (2.5/5.0): The audit strengthened the evidence base with 2024-2026 systematic reviews, but evidence quality remains the bottleneck. Pasqualotto 2024, Tewari 2025, Misra 2025, Abulehia 2026, and Chan 2026 all support efficacy. But many pooled estimates recycle the same small retatrutide RCT base, indirect comparisons, and Lilly-funded trials. There is no FDA label, no post-marketing pharmacovigilance, no completed cardiovascular outcomes publication, and no retatrutide-specific Cochrane review.
Speed of Onset (3.8/5.0): Retatrutide starts quickly for appetite, then compounds over months. Appetite suppression often appears within 1-2 weeks, as expected for GLP-1-containing incretin therapy. HbA1c begins moving within the first several weeks and was clearly reduced by the primary timepoint in Rosenstock 2023. Weight loss is not instant, but it is steady and large through 24-48 weeks. Liver-fat changes in Sanyal 2024 were measured at 24 weeks. Side effects can also start quickly, which is why titration matters.
Durability (1.5/5.0): Retatrutide has no published off-drug durability dataset. The best assumption comes from the broader incretin class: appetite and weight regulation effects fade when drug exposure falls, and weight regain is common without an intensive maintenance plan. Retatrutide's larger weight-loss magnitude may make rebound more consequential, especially if lean mass was lost during the active phase. For chronic metabolic disease, indefinite treatment may be acceptable under medical supervision. For cosmetic use, this creates a long commitment many users underestimate.
Bioindividuality Upside (4.8/5.0): Retatrutide's responder curve is unusually broad in obesity Phase 2. The v0.x data extract noted that 100% of 12 mg completers achieved at least 5% weight loss, 83% achieved at least 15%, 63% achieved at least 20%, and 26% achieved at least 30%. That pattern makes retatrutide less dependent on a small super-responder tail than many interventions. The best candidates are people with obesity, insulin resistance, high liver fat, type 2 diabetes, or weight-related mechanical disease. Lean, metabolically healthy, athletic, or under-muscled users face a much worse trade-off.
Downside contribution: 4.39 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 4.0 | 1.200 | |
| Side Effect Profile | 15% | 3.3 | 0.495 | |
| Financial Cost | 5% | 3.8 | 0.190 | |
| Time/Effort Burden | 5% | 1.5 | 0.075 | |
| Opportunity Cost | 5% | 2.2 | 0.110 | |
| Dependency / Withdrawal | 15% | 4.0 | 0.600 | |
| Reversibility | 25% | 2.3 | 0.575 | |
| Total | 3.245 | |||
| Harm subtotal × 1.4 | 4.018 | |||
| Opportunity subtotal × 1.0 | 0.375 | |||
| Combined downside | 4.393 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 3.053 |
Downside Rationale
Retatrutide's downside starts with approval status and long-term safety uncertainty, not with a simple claim that Retatrutide is dangerous for everyone. Sanyal 2024 is the most useful caution anchor in the verified pool, and the broader tradeoff is that long-term safety, muscle preservation, discontinuation effects, and real-world sourcing remain unsettled. The risk also depends on context: unapproved compounded products, pregnancy, pancreatitis or gallbladder history, severe GI effects, and medical oversight can change the equation fast. That matters because a modest or uncertain upside has to clear a higher bar when the user has contraindications, poor tracking, or unrealistic expectations. In practice, Retatrutide deserves a narrow trial, conservative dosing or exposure, and a stop rule tied to body composition, glucose, liver fat, blood pressure, GI symptoms, gallbladder risk, and lean mass.
Safety Risk (4.0/5.0): Retatrutide's safety risk is high because the compound is potent, unapproved, and not yet observed long enough to detect rare serious harms. FDA says retatrutide has not been found safe and effective for any condition and cannot legally be compounded. The Phase 2 sample is too small to settle pancreatitis, gallbladder disease, severe gastroparesis, thyroid C-cell risk, retinopathy risk during rapid glucose improvement, or cardiovascular consequences of heart-rate increase. The novel glucagon arm is the key unknown. Trial monitoring helps; gray-market self-use removes that protection.
Side Effect Profile (3.3/5.0): Gastrointestinal effects are the practical limiting factor. Jastreboff 2023 reported dose-related nausea, diarrhea, vomiting, constipation, and discontinuation. Rosenstock 2023 found a similar pattern in type 2 diabetes, with gastrointestinal adverse events rising at higher doses. Heart-rate increase matters because it is larger than many users expect from a weight-loss drug. Rapid weight loss also creates lean-mass, gallstone, under-fueling, and excessive-weight-loss risk. These effects are titration-sensitive but not trivial.
Financial Cost (3.8/5.0): Retatrutide has no legal pharmacy price because it is not approved. Gray-market research-peptide pricing commonly advertises around $200-400 per month, but that price buys uncertainty around identity, sterility, storage, and dose. If approved, retatrutide will likely price like branded incretins, often $1,000+ per month cash before insurance. That creates a multi-year cost burden for a drug likely requiring maintenance therapy.
Time/Effort Burden (1.5/5.0): Administration effort is low when product and supervision are legitimate: one subcutaneous injection weekly, stepwise titration, rotating injection sites, and standard monitoring. Trial pens remove reconstitution work. Gray-market use adds aseptic mixing, vial math, storage, dose calculation, and quality-control uncertainty. The effort score stays low for the clinical protocol, but unsupervised users should not confuse low time burden with low risk.
Opportunity Cost (2.2/5.0): Retatrutide can crowd out the habits that make weight loss durable. Appetite suppression can reduce protein intake, training appetite, meal structure, and social eating. Users who do not resistance train and maintain adequate protein are more likely to lose lean mass. The better use case is as an adjunct to diet quality, walking, resistance training, sleep, and cardiometabolic monitoring. Endocrine Society guidance for obesity pharmacotherapy keeps behavioral modification in the foundation, not as an optional add-on.
Dependency/Withdrawal (4.0/5.0): Retatrutide has no known addictive withdrawal syndrome, but functional dependency is high. The drug works by suppressing appetite, altering incretin signaling, and changing hepatic energy handling. When exposure drops below the active threshold, those effects should fade. Off-drug retatrutide data are absent, so the conservative assumption is class-like regain unless nutrition, training, sleep, and environment have changed. For chronic disease, ongoing therapy may be reasonable. For short cosmetic cycles, this is a major downside.
Reversibility (2.3/5.0): Most pharmacology should reverse after discontinuation as gastric emptying, appetite, glucose handling, and body weight regulation return toward baseline. The harder-to-reverse part is body composition. Rapid loss without strength training can remove lean mass, and regain often returns disproportionately as fat. Rare events such as pancreatitis, severe gastroparesis, gallbladder disease, or retinopathy worsening are not guaranteed to reverse on a neat schedule. That is why reversibility is meaningfully worse than a lifestyle intervention.
Verdict
Retatrutide is a 4.5/10 fit for people following obesity, diabetes, liver-fat, or cardiometabolic drug development under medical supervision, because retatrutide has unusually large Phase 2 metabolic effects, but it is still investigational. Jastreboff 2023 gives the strongest anchor, while Rosenstock 2023 adds useful context without closing the case. The honest gap is simple: long-term safety, muscle preservation, discontinuation effects, and real-world sourcing remain unsettled. That puts Retatrutide in the tracked-experiment category, not the automatic-staple category. In practice, Retatrutide makes the most sense when you monitor body composition, glucose, liver fat, blood pressure, GI symptoms, gallbladder risk, and lean mass and avoid treating Retatrutide like an approved or casual peptide shortcut.
✅ Best for: Retatrutide is best for adults in Lilly-run clinical trials with severe obesity or obesity plus type 2 diabetes, MASLD/MASH, obstructive sleep apnea, knee osteoarthritis, or cardiovascular risk, where manufactured product, titration, laboratory monitoring, and adverse-event tracking are built in. If retatrutide receives FDA approval with a clean label, the strongest fit will be metabolically high-risk obesity after standard lifestyle work and approved alternatives have been considered. It is also best paired with resistance training, 1.6+ g/kg protein when clinically appropriate, and active monitoring for gallbladder, pancreatic, heart-rate, glucose, and lean-mass issues.
❌ Avoid if: Avoid retatrutide if you are sourcing research peptide online, treating it as a cosmetic cut, or using it for longevity microdosing. Avoid without specialist oversight if you have personal or family history of MTC or MEN2, prior pancreatitis, severe gastroparesis, active eating disorder, pregnancy plans, significant cardiovascular disease, advanced kidney disease, insulin or sulfonylurea use, or known diabetic retinopathy risk during rapid glucose improvement. Tested athletes should also treat retatrutide as high-risk under WADA S0 unless their sport authority confirms otherwise.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Metabolic Health: 8.5/10
Score: 8.5/10Retatrutide earns 8.5/10 for metabolic-health because Jastreboff 2023 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: Triple agonism targets appetite, glucose control, weight, waist circumference, and cardiometabolic markers. this verified source and this verified source support the strongest. That does not make Retatrutide a targeted metabolic-health treatment. The report's best evidence is mostly Phase 2 metabolic data, not long-term outcomes or wellness use, so the score is directional rather than settled. Track fasting glucose, waist, energy, and appetite, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Body Composition / Fat Loss: 7.5/10
Score: 7.5/10Retatrutide's 7.5/10 body-composition score starts with Jastreboff 2023, then gets narrowed by the evidence gap. The existing rationale points to this narrower claim: Body-weight loss is historically large for a drug class, with up to 24.2% in this verified source. Body-composition quality depends on resistance. That does not make Retatrutide a targeted body-composition treatment. The report's best evidence is mostly Phase 2 metabolic data, not long-term outcomes or wellness use, so the score is directional rather than settled. Track body composition, strength, soreness, and training logs, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Blood Sugar / Glycemic Control: 8.0/10
Score: 8.0/10The blood-sugar case for Retatrutide is 8.0/10 because Sanyal 2024 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: this verified source reported HbA1c reductions up to -2.02% in type 2 diabetes, with additional 2026 Lilly topline Phase 3 results directionally. That does not make Retatrutide a targeted blood-sugar treatment. The report's best evidence is mostly Phase 2 metabolic data, not long-term outcomes or wellness use, so the score is directional rather than settled. Track fasting glucose, post-meal response, and energy stability, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Liver / Detoxification: 8.0/10
Score: 8.0/10For liver-detox, Retatrutide lands at 8.0/10 because Rosenstock 2023 supports the strongest part of the claim. The existing rationale points to this narrower claim: The glucagon receptor arm is designed to raise hepatic fat oxidation, and this verified source reported large liver-fat reductions in MASLD. The. That does not make Retatrutide a targeted liver-detox treatment. The report's best evidence is mostly Phase 2 metabolic data, not long-term outcomes or wellness use, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Cardiovascular: 6.0/10
Score: 6.0/10On cardiovascular, Retatrutide deserves 6.0/10 because Rosenstock 2023 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Weight, blood pressure, triglyceride, glucose, and inflammation markers likely move favorably, but no completed cardiovascular outcomes trial exists. this verified source documents. That does not make Retatrutide a targeted cardiovascular treatment. The report's best evidence is mostly Phase 2 metabolic data, not long-term outcomes or wellness use, so the score is directional rather than settled. Track heart rate, pace, blood pressure, and recovery, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Hormonal / Endocrine: 5.5/10
Score: 5.5/10A 5.5/10 for hormonal fits Retatrutide because Sanyal 2024 supports direction more than certainty. The existing rationale points to this narrower claim: Insulin normalization and large fat loss can improve obesity-linked sex-hormone patterns. Direct endocrine outcomes are not retatrutide endpoints yet, and thyroid C-cell. That does not make Retatrutide a targeted hormonal treatment. The report's best evidence is mostly Phase 2 metabolic data, not long-term outcomes or wellness use, so the score is directional rather than settled. Track lab work, libido, sleep, and mood, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
Anti-Inflammatory: 5.0/10
Score: 5.0/10The practical anti-inflammatory read on Retatrutide is 5.0/10 because Jastreboff 2023 anchors the strongest signal. The existing rationale points to this narrower claim: Inflammation may improve secondarily through fat loss, liver-fat reduction, and metabolic improvement. Direct inflammatory-disease trials are not available; Lilly's TRIUMPH-4 topline included. That does not make Retatrutide a targeted anti-inflammatory treatment. The report's best evidence is mostly Phase 2 metabolic data, not long-term outcomes or wellness use, so the score is directional rather than settled. Track symptoms, labs, performance, recovery, and a clear before-after marker, then stop if the signal is absent or the tradeoff becomes larger than the benefit.
| Use Case | Score | Summary |
|---|---|---|
| ○ Bone / Joint Health Primary | 4.5 | Weight loss reduces mechanical knee load, and Lilly's TRIUMPH-4 topline reported WOMAC pain improvements in obesity with knee osteoarthritis. Full peer-reviewed data are still pending, so the v0.x score remains held. |
| ○ Respiratory Primary | 3.5 | Obstructive sleep apnea is in the TRIUMPH development program and weight loss should reduce apnea burden, but retatrutide-specific peer-reviewed sleep-apnea outcomes are still pending. |
| ○ Healthspan | 4.5 | Metabolic disease improvement could extend healthspan in high-risk obesity, but retatrutide has no long-term morbidity, mortality, cancer, dementia, or frailty outcomes. Authority gaps keep this from becoming a broad healthspan recommendation. |
| ○ Chronic Pain Management | 4.0 | Pain benefit is likely indirect through weight loss and reduced joint load. Knee osteoarthritis is the most relevant signal, but retatrutide is not a general analgesic and chronic pain endpoints remain narrow. |
| ○ Geriatric / Aging Population | 4.0 | Older adults with obesity may benefit metabolically, but sarcopenia, frailty, dehydration, falls, polypharmacy, and appetite suppression make unsupervised use risky. No geriatric-specific retatrutide outcomes establish net benefit. |
| ○ Flexibility / Mobility | 3.5 | Large weight loss can improve mobility in severe obesity and knee osteoarthritis. The effect is mediated by mass reduction, pain reduction, and function, not direct effects on flexibility or connective-tissue quality. |
| ○ Acute Pain Relief | 3.5 | Retatrutide is not an acute pain drug. Any pain relief is downstream of slower weight loss and joint-load reduction, which does not match the timeline or mechanism of analgesic interventions. |
| ○ Sleep Quality | 3.5 | Weight loss may improve sleep apnea and reflux, but nausea, under-eating, and dysesthesia could disturb sleep in some users. No sleep-quality RCT endpoint justifies a higher score yet. |
| ○ Longevity / Lifespan | 3.0 | Retatrutide has no lifespan or long-term disease-outcome evidence. Treating it as a longevity intervention in healthy adults overreaches the data and ignores the FDA and authority gaps documented in the audit. |
| ○ Endurance / Cardio | 3.0 | Lower body mass can improve relative endurance in people with obesity, but caloric deficit, nausea, and lean-mass loss can impair training. No retatrutide exercise-performance trial supports direct endurance benefit. |
| ○ Energy / Fatigue | 3.0 | Glucagon is thermogenic and weight loss can improve daily energy in metabolic disease, but nausea and sustained caloric deficit can reduce energy. Retatrutide has no direct fatigue or vitality endpoint. |
Frequently Asked Questions
How does retatrutide work and why does it produce more weight loss than semaglutide or tirzepatide?
Retatrutide activates GLP-1, GIP, and glucagon receptors in one molecule. GLP-1 and GIP reduce appetite and improve insulin signaling; glucagon is intended to raise hepatic fat oxidation and energy expenditure. Coskun 2022 established the discovery and proof-of-concept biology, and Jastreboff 2023 showed up to 24.2% body-weight loss at 48 weeks.
What are the approved clinical doses and realistic gray-market protocols?
There is no approved retatrutide dose. Clinical trials use once-weekly subcutaneous dosing with gradual escalation, commonly starting at 2 mg and stepping every 4 weeks toward 8 mg, 9 mg, or 12 mg. Giblin 2026 describes TRIUMPH protocols. Gray-market microdosing and dose skipping are unsupported and add product-quality risk.
How does retatrutide efficacy actually compare to semaglutide and tirzepatide?
Retatrutide appears stronger for weight loss in indirect comparisons, but head-to-head trials are not available. Jastreboff 2023 reported up to 24.2% at 48 weeks, while Xie 2024 ranked 12 mg and 8 mg retatrutide as the strongest options in a network meta-analysis. The evidence base is smaller than for approved GLP-1 drugs.
What safety signals have appeared in the Phase 2 data and which class risks carry over?
The main retatrutide safety signals are gastrointestinal tolerability, dose-related discontinuation, heart-rate increase, dysesthesia, and unknown long-term risk. Jastreboff 2023 reported dose-dependent gastrointestinal adverse events and heart-rate increases. Class concerns also include pancreatitis, gallbladder disease, severe delayed gastric emptying, thyroid C-cell labeling precedent, and retinopathy concerns during rapid glucose improvement.
Who should avoid retatrutide entirely?
Avoid retatrutide outside clinical trials if you have a personal or family history of medullary thyroid carcinoma or MEN2, prior pancreatitis, severe gastroparesis, active eating disorder, pregnancy plans, or significant cardiovascular disease without specialist oversight. FDA also says retatrutide is not approved and cannot legally be compounded.
What is the expected timeline for effects, plateau, and off-drug regain?
Appetite suppression can start within 1-2 weeks, glycemia changes within weeks, and body weight continued falling through 48 weeks in the obesity Phase 2 trial. Jastreboff 2023 did not establish off-drug durability. Based on approved incretin precedent, stopping therapy likely means appetite returns and much of the weight can rebound without a maintenance plan.
Is gray-market retatrutide safe to source, and how does it differ from pharmacy-compounded semaglutide?
Gray-market retatrutide is not a safe pharmacy substitute. Retatrutide lacks an approved reference drug, and FDA says it cannot be used in compounding under federal law. FDA also warns that research-use-only GLP-1 products sold to consumers may be unapproved drugs of unknown quality. That is categorically different from a regulated approved prescription product.
Do biohacker microdoses make sense for longevity or metabolic tuning in healthy adults?
No human evidence supports retatrutide microdosing for longevity. The published therapeutic program targets obesity, type 2 diabetes, MASLD/MASH, sleep apnea, and weight-related mechanical disease. Healthy users inherit class risks, unapproved-drug risk, and product-quality risk for speculative benefit. Diet quality, resistance training, Zone 2 cardio, sleep, and approved care beat this risk profile.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| TRIUMPH cardiovascular outcomes trial reports 20%+ MACE reduction with clean tolerability | Evidence 2.5 to 3.5; Breadth 3.8 to 4.3 | 4.4 / 10 ⚖️ Neutral |
| FDA approves retatrutide and 2-year safety data stay clean | Evidence 2.5 to 4.0; Safety 4.0 to 3.5; Breadth 3.8 to 4.3 | 4.6 / 10 ⚖️ Neutral |
| Phase 3 or post-marketing data surface thyroid C-cell, pancreatitis, or cardiac signal | Safety 4.0 to 5.0; Side effects 3.3 to 4.5 | 3.5 / 10 ⚠️ Proceed with caution |
| FDA approval plus 5-year clean safety and meaningful off-drug durability data | Evidence 2.5 to 4.5; Safety 4.0 to 3.5; Durability 1.5 to 2.5 | 4.9 / 10 ⚖️ Neutral |
| Population-specific scoring for obese adults with type 2 diabetes and MASH under physician care | Efficacy remains 4.9; Breadth 3.8 to 4.2; Opportunity 2.2 to 1.8 | 4.8 / 10 ⚖️ Neutral |
Key Evidence Sources
- Jastreboff AM et al. 2023 - Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial, New England Journal of Medicine. Phase 2 obesity RCT; up to 24.2% body-weight loss at 48 weeks; gastrointestinal adverse events and heart-rate increases were dose-related
- Rosenstock J et al. 2023 - Retatrutide for people with type 2 diabetes: randomized phase 2 trial, Lancet. Phase 2 T2D RCT; HbA1c reduction up to -2.02% at 24 weeks and body-weight loss up to -16.94% at 36 weeks
- Coskun T et al. 2022 - LY3437943 discovery to clinical proof of concept, Cell Metabolism. Mechanism, preclinical pharmacology, phase 1 proof of concept, once-weekly pharmacokinetic rationale
- Sanyal AJ et al. 2024 - Triple hormone receptor agonist retatrutide for MASLD: randomized phase 2a trial, Nature Medicine. Audit-verified MASLD phase 2a source; excluded from Track 1 n>=100 threshold but relevant for liver-fat signal
- Xie Z et al. 2024 - Seven GLP-1 receptor agonists and polyagonists for weight loss: updated network meta-analysis, Metabolism. 27 RCTs and 15,584 participants; retatrutide 12 mg and 8 mg ranked strongest for weight loss in indirect comparison
- Pasqualotto E et al. 2024 - Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: systematic review and meta-analysis, Metabolism Open. 3 placebo-controlled RCTs; retatrutide reduced body weight, BMI, and waist circumference, while increasing non-severe gastrointestinal and hypersensitivity adverse events
- Tewari J et al. 2025 - Efficacy and safety of triple hormone receptor agonist retatrutide for obesity: systematic review and meta-analysis, Expert Review of Clinical Pharmacology. 4 RCTs; dose-response pattern with largest reductions at 12 mg; safety described as comparable to control in fetched abstract
- Misra S et al. 2025 - Efficacy and safety of retatrutide for obesity: systematic review of clinical trials, Journal of Basic and Clinical Physiology and Pharmacology. 691 randomized participants in fetched abstract; 12 mg produced largest reductions in body weight, BMI, and waist circumference
- Pallavi K et al. 2025 - Retatrutide in diabetes and/or obesity comorbid with chronic kidney disease: systematic review and meta-analysis, Maedica. 8 included studies; HbA1c and weight benefits reported, with gastrointestinal adverse events as main tolerability issue
- Abulehia A et al. 2026 - Comparative efficacy and safety of glucagon receptor agonists on metabolic outcomes: network meta-analysis, Endocrinology, Diabetes & Metabolism. 14 RCTs and 3,102 participants; retatrutide had the largest weight and HbA1c effects among glucagon receptor agonist-based agents, with lower tolerability than some comparators
- Chan ZH et al. 2026 - Incretin-based dual and triple agonists in overweight or obese individuals: systematic review and meta-analysis, Current Reviews in Clinical and Experimental Cardiology. 10 RCTs and 3,236 participants; incretin dual/triple agonists reduced weight, waist circumference, HbA1c, and fasting plasma glucose; gastrointestinal adverse events increased
- Giblin K et al. 2026 - TRIUMPH registrational clinical trials rationale and design, Diabetes, Obesity and Metabolism. Phase 3 program design for obesity, obstructive sleep apnea, and knee osteoarthritis; design source, not outcomes proof
- Ramsbacher N 2024 - Retatrutide, Clinical Diabetes. Short clinical drug overview summarizing retatrutide's investigational status, mechanism, and emerging clinical data
- Lilly 2025 - TRIUMPH-4 topline obesity and knee osteoarthritis Phase 3 press release. Company-reported topline results: up to 28.7% body-weight loss and WOMAC pain improvement at 68 weeks; not peer-reviewed at audit close
- Lilly 2026 - TRANSCEND-T2D-1 topline type 2 diabetes Phase 3 press release. Company-reported topline T2D Phase 3 results: A1C reductions and 12 mg weight loss; not peer-reviewed at audit close
- FDA 2026 - Concerns with unapproved GLP-1 drugs used for weight loss. FDA states retatrutide cannot be used in compounding, is not a component of an FDA-approved drug, and has not been found safe and effective for any condition
- WADA 2026 - Prohibited List S0 Non-Approved Substances. Non-approved pharmacological substances with no current governmental approval for human therapeutic use are prohibited at all times under S0
- Endocrine Society 2016 - Pharmacological Management of Obesity Guideline Resources. Obesity pharmacotherapy guidance supports approved-label medication use with diet, exercise, behavior change, and ongoing efficacy/safety monitoring
- USPSTF 2018 - Behavioral Interventions for Adults With Obesity. Preventive-care authority recommends intensive multicomponent behavioral intervention for adults with BMI 30 or higher; no retatrutide-specific endorsement
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Jastreboff 2023, Rosenstock 2023, Coskun 2022, Sanyal 2024, Xie 2024, Pasqualotto 2024, Pallavi 2025, Abulehia 2026, Chan 2026, Giblin 2026
Pre-RCT-Era Pharmacology and Use
Confidence: Limited
Citations: Coskun 2022, Jastreboff 2023, Rosenstock 2023, Giblin 2026
Traditional Medicine Systems
Confidence: Limited
Holistic Evidence for Retatrutide
The evidence lenses do not converge in the way they might for light, fasting, sauna, or botanicals. Modern clinical pharmacology gives retatrutide a very large efficacy signal. Historical pharmaceutical development shows rapid progression but short observation time. Traditional evidence contributes almost nothing because the molecule is synthetic and new. That split is exactly why the score remains neutral: the benefit signal is unusually strong, while authority status, independent replication, post-marketing safety, and off-drug durability are still unresolved.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- HbA1c Baseline (pre-protocol)
- Fasting Glucose During | Expected Down
- Fasting Insulin During | Expected Down
- Triglycerides During | Expected Down
- ALT During | Expected Stable
- AST During | Expected Stable
- Lipase During | Expected Stable
Pulse Dimensions to Watch
- Body During | Expected Up | Primary
- Energy During | Expected Watch | Secondary
- Drive During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Appetite Scale 1-5 | During | Expected Down
- Nausea Scale 1-5 | During | Expected Watch
- Exercise Tolerance Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Persistent vomiting or dehydration
- Severe abdominal pain
- Blood in stool or black stool
- Symptoms of pancreatitis: severe upper abdominal pain radiating to back
Other interventions for Metabolic Health
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 2.670 − 3.053 = -0.383
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (-0.383 / 7) × 5 = 4.7 / 10
Further learning
13 Top Peptides Companies Review & Test 2026: Where I Buy Peptides Online
After a decade in the peptide industry, I reviewed and ranked 13 reputable peptide companies across two tiers. Your source can mean the difference…
Fat Loss Peptides & Fasting: Body Recomposition Plan
Uncover the tools in Jay Campbell's new book “30 Days to Shredz.” Discover the power of intermittent fasting and performance enhancers for rapid fat…
